Literature DB >> 16939410

Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.

Satoshi Yasuda1, Shunichi Miyazaki, Hideyuki Kinoshita, Noritoshi Nagaya, Munetake Kanda, Yoichi Goto, Hiroshi Nonogi.   

Abstract

Previous experimental studies have demonstrated that MMPs (matrix metalloproteinases) contribute to LV (left ventricular) remodelling. We hypothesized that cardiac MMPs are activated in patients with AMI (acute myocardial infarction) and, if so, MMP production may be attenuated by statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) through their cardiovascular protective actions. We studied 30 patients, ten control patients with stable angina pectoris and 20 patients with AMI, in whom LV catheterization at the chronic stage was performed 22+/-12 days (value is mean+/-S.D.) after the onset of AMI. Blood samples were collected from the CS (coronary sinus) and a peripheral artery. In patients with AMI, the levels of MMP-2 and MMP-9 were significantly (P<0.05) higher in the CS than the peripheral artery (MMP-2, 853+/-199 compared with 716+/-127 ng/ml; MMP-9, 165+/-129 compared with 98+/-82 ng/ml), whereas no significant differences were observed in the patients with angina pectoris. The CS-arterial concentration gradients of MMP-2 and MMP-9 correlated positively with BNP (brain natriuretic peptide) levels (MMP-2, R=0.68, P<0.01; MMP-9, R=0.59, P<0.05) and LV end-diastolic volume index (MMP-2, R=0.70, P<0.01; MMP-9, R=0.70, P<0.01). When patients with AMI treated with 10 mg of pravastatin or without (n=10 in each group) were compared, this statin therapy significantly (P<0.05) decreased the CS-arterial concentration gradients of MMP-2 (69+/-43 compared with 213+/-185 ng/ml) and MMP-9 (14+/-27 compared with 119+/-84 ng/ml). In conclusion, the enhanced production of cardiac MMP-2 and MMP-9 is associated with LV enlargement and elevated BNP levels in patients with AMI. A pleiotropic effect of statins appears to be associated with the modulation of cardiac MMP activation, which may be potentially beneficial in the attenuation of post-infarction LV remodelling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16939410     DOI: 10.1042/CS20060110

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

Review 1.  MMPs as therapeutic targets--still a viable option?

Authors:  Barbara Fingleton
Journal:  Semin Cell Dev Biol       Date:  2007-07-06       Impact factor: 7.727

2.  Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.

Authors:  Akhilesh Kumar; Shephali Bhatnagar; Ashok Kumar
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

3.  Association of polymorphisms of zinc metalloproteinases with clinical response to stem cell therapy.

Authors:  R Panovsky; A Vasku; J Meluzin; M Kaminek; J Mayer; S Janousek; V Kincl; L Groch; M Navratil
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

Review 4.  Myocardial remodeling: cellular and extracellular events and targets.

Authors:  Jennifer A Dixon; Francis G Spinale
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

Review 5.  Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.

Authors:  Kristine Y DeLeon-Pennell; Cesar A Meschiari; Mira Jung; Merry L Lindsey
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-18       Impact factor: 3.622

Review 6.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.

Authors:  Uma Singh; Sridevi Devaraj; Ishwarlal Jialal; David Siegel
Journal:  Am J Cardiol       Date:  2008-05-28       Impact factor: 2.778

Review 8.  Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Rugmani Padmanabhan Iyer; Michael E Hall; Merry L Lindsey
Journal:  Physiology (Bethesda)       Date:  2013-11

Review 9.  Structural aspects of Golgi function.

Authors:  R S Polishchuk; A A Mironov
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 10.  Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.

Authors:  Yuji Ogura; Marjan M Tajrishi; Shuichi Sato; Sajedah M Hindi; Ashok Kumar
Journal:  Front Cell Dev Biol       Date:  2014-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.